HLA-A and myeloid sarcoma: This analysis further revealed that European HLA-B*07:02 (OR = 1.66, 95% CI: 1.12–2.47, p = 1.18 × 10−2) and HLA-A*03:01 (OR = 1.54, 95% CI: 1.04–2.29, p = 2.97 × 10−2) conferred a greater risk of MS compared to their African counterparts at p < 0.05.